Latin America was Summit Therapeutics’s largest region in fiscal 2019, bringing in $457.00K of $583.00K (78%).
| Geography | FY 2017 | FY 2018 | FY 2019 | FY 2019 |
|---|---|---|---|---|
| United States | $2.30M | $12.01M | $42.27M | $126.00K |
| Latin America | — | $42.00K | $499.00K | $457.00K |
| Europe | — | $310.00K | $246.00K | — |
| Total | $2.30M | $12.36M | $43.01M | $583.00K |
Summit Therapeutics brought in $583.00K from its two regions in fiscal 2019, the year ended December 31, 2019. Summit Therapeutics regrouped these regions after fiscal 2019, so the total does not compare directly with that year's $43.01M. Latin America was the largest at $457.00K (78.4%), ahead of United States at $126.00K (21.6%).
Compared with fiscal 2019, Latin America fell 8.4% to $457.00K and United States fell 99.7% to $126.00K.
Summit Therapeutics began breaking out Latin America in fiscal 2018, when it brought in $42.00K. Summit Therapeutics stopped reporting Europe as a separate region after fiscal 2019, when it brought in $246.00K.
Licensing Agreements was Summit Therapeutics’s largest revenue line in fiscal 2019, bringing in $42.77M of $43.01M (99%).
| Products and services [axis] | FY 2017 | FY 2018 | FY 2019 |
|---|---|---|---|
| Licensing Agreements | $2.30M | $12.05M | $42.77M |
| Research Collaboration Agreement | — | $310.00K | $246.00K |
| Total | $2.30M | $12.36M | $43.01M |
Summit Therapeutics brought in $43.01M from its two revenue lines in fiscal 2019, the year ended January 31, 2019. That was up 248.0% from $12.36M in fiscal 2018. Licensing Agreements was the largest at $42.77M (99.4%), ahead of Research Collaboration Agreement at $246.00K (0.6%).
Summit Therapeutics began breaking out Research Collaboration Agreement in fiscal 2018, when it brought in $310.00K.
Summit Therapeutics (SMMT) reports its revenue by geography and by products and services [axis]. In fiscal 2019, Latin America was its largest region, bringing in $457.00K (78.4% of the total), followed by United States at $126.00K (21.6%).
Latin America was Summit Therapeutics' largest region in fiscal 2019, bringing in $457.00K, or 78.4% of the $583.00K total across its two regions.
Licensing Agreements was Summit Therapeutics' largest revenue line in fiscal 2019, bringing in $42.77M, or 99.4% of the $43.01M total across its two revenue lines.
Every figure comes from Summit Therapeutics' annual financial filings, as reported. Each line keeps the name Summit Therapeutics gives it, and years follow its fiscal calendar.
Summit Therapeutics' revenue by geography goes back to fiscal 2017, with figures through fiscal 2019. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.